{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:41Z","timestamp":1781643521337,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Most patients with metastatic hormone-sensitive prostate cancer (mHSPC) are burdened by bone metastases. However, the impact of concomitant distant lymph node metastases at diagnosis in these patients is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We relied on a single-center retrospective mHSPC patient cohort treated between 2014 and 2024 to compare time to metastatic castration-resistant prostate cancer (mCRPC) and overall survival (OS) between M1b vs. M1a\u2009+\u2009b mHSPC patients. Univariable and multivariable Cox regression models were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 432 patients, 64% harbored M1b vs. 36% M1a\u2009+\u2009b mHSPC. Median PSA was numerically higher (82 vs. 46 ng\/ml,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2) and rates of LATITUDE high-risk (76% vs. 55%) and CHAARTED high-volume disease (70% vs. 50%) were significantly higher in the M1a\u2009+\u2009b group (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Regarding time to mCRPC, median time to CRPC was 26 vs. 16 months for M1b vs. M1a\u2009+\u2009b patients (hazard ratio [HR]: 1.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Regarding OS, median OS was not significantly different, with median OS of 53 vs. 47 months for M1b vs. M1a\u2009+\u2009b patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.9). After controlling for patient and tumor characteristics in multivariable Cox regression analyses, concomitant lymph node metastases were not an independent risk for shorter time to CRPC or OS in patients with bone metastases (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with concomitant distant lymph node metastases in mHSPC with bone metastases (M1a\u2009+\u2009b) harbor more unfavorable baseline cancer characteristics relative to M1b without lymph node metastases, translating into significantly shorter time to mCRPC. However, after controlling for patient and tumor characteristics, neither time to mCRPC nor OS seems not be affected by concomitant lymph node metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06358-5","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:48:47Z","timestamp":1774334927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases"],"prefix":"10.1007","volume":"44","author":[{"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Giuseppe","family":"M\u00fchlthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Filzmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kosiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kriegmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"6358_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A, Cancer statistics (2019) CA: a cancer journal for clinicians. 69: 7\u201334","DOI":"10.3322\/caac.21551"},{"key":"6358_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin 71:209\u2013249","journal-title":"Cancer J Clin"},{"key":"6358_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2023-0814","volume":"20","author":"PJ Goebell","year":"2024","unstructured":"Goebell PJ, Raina R, Chen S, Rege S, Shah R, Grossman JP, Waldeck AR (2024) Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol (London England) 20:903\u2013918","journal-title":"Future Oncol (London England)"},{"key":"6358_CR4","unstructured":"Cornford P, Tilki D, van den Bergh RCN et al (2024) EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Paris 2024: ISBN 978-94-92671-23-3"},{"key":"6358_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686\u2013700","journal-title":"Lancet Oncol"},{"key":"6358_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin oncology: official J Am Soc Clin Oncol 36:1080\u20131087","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"6358_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","volume":"8","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, W\u00fcrnschimmel C, Nocera L, Coll\u00e0 Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI (2022) Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Eur Urol focus 8:399\u2013408","journal-title":"Eur Urol focus"},{"key":"6358_CR8","unstructured":"Brierley J, Gospodarowicz MK, Wittekind C, Eds (2017) TNM classification of malignant tumours; John Wiley & Sons Inc; Wiley Blackwell: Chichester, West Sussex, UK, Hoboken, NJ, Chichester, West Sussex"},{"key":"6358_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 68:325\u2013334","journal-title":"Eur Urol"},{"key":"6358_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","volume":"65","author":"GR Pond","year":"2014","unstructured":"Pond GR, Sonpavde G, Wit R (2014) The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 65:3\u20136EisenbergerM.A.Tannock, I.F.; Armstrong, A.J","journal-title":"Eur Urol"},{"key":"6358_CR11","unstructured":"Deutsche Krebsgesellschaft D, Krebshilfe AWMF (2024) (Leitlinienprogramm Onkologie). S3-Leitlinie Fr\u00fcherkennung, Diagnose und Therapie des Prostatakarzinoms: Version 6.1"},{"key":"6358_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00345-024-05388-1","volume":"43","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Humke C, Cano Garcia C, Siech C, Steuber T, Graefen M, Traumann M, Kluth L, Chun FKH, Mandel P (2024) Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer. World J Urol 43:51","journal-title":"World J Urol"},{"key":"6358_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.euros.2025.05.001","volume":"77","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Steuber T, Siech C, Kriegmair M, Hoeh B, Tilki D, Merseburger AS, Chun FKH, Mandel P (2025) Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer. Eur Urol open Sci 77:19\u201322","journal-title":"Eur Urol open Sci"},{"key":"6358_CR14","doi-asserted-by":"publisher","first-page":"659135","DOI":"10.3389\/fonc.2021.659135","volume":"11","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Preisser F, Hoeh B, Schroeder M, W\u00fcrnschimmel C, Steuber T, Heinzer H, Banek S, Ahrens M, Becker A, Karakiewicz PI, Chun FKH, Kluth LA, Mandel P (2021) Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies. Front Oncol 11:659135","journal-title":"Front Oncol"},{"key":"6358_CR15","doi-asserted-by":"publisher","first-page":"175628722412975","DOI":"10.1177\/17562872241297579","volume":"16","author":"MI Elewaily","year":"2024","unstructured":"Elewaily MI, Campione M, Hassan MA, Anpalakhan S, Atsumi N, Smalley B, Ashraf A, Gale J, Maniam A, Banna GL (2024) Prognostic factors and treatment choice for stage IV, low-volume metastasis hormone-sensitive prostate cancer: cross-sectional study of real-world data. Ther Adv Urol 16:17562872241297579","journal-title":"Ther Adv Urol"},{"key":"6358_CR16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.21873\/anticanres.13253","volume":"39","author":"H Miyake","year":"2019","unstructured":"Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A (2019) Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer. Anticancer Res 39:1391\u20131396","journal-title":"Anticancer Res"},{"key":"6358_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4103\/aja202270","volume":"25","author":"Z-P Wang","year":"2023","unstructured":"Wang Z-P, Chen J-R, Zhao J-G, Zhu S, Zhang X-M, Liang J-Y, He B, Ni Y-C, Sun G-X, Shen P-F, Zeng H (2023) Regional location of lymph node metastases predicts survival in patients with de novo metastatic prostate cancer. Asian J Androl 25:462\u2013467","journal-title":"Asian J Androl"},{"key":"6358_CR18","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, Bono J (2016) Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. JCO 34:1652\u20131659ArmstrongA.J.Eisenberger, M.A.; Fandi, A.; Li, S.; Araujo, J.C.; Logothetis, C.J.; Quinn, D.I.; Morris, M.J.; Higano, C.S.; Tannock, I.F.; Small, E.J.","journal-title":"JCO"},{"key":"6358_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1055\/a-2129-7206","volume":"55","author":"P Paffenholz","year":"2024","unstructured":"Paffenholz P, Roesch MC (2024) Medikament\u00f6se Tumortherapie des mHSPC: Double- oder Tripletherapie: wer, wann und wie? Aktuelle Urologie 55:116\u2013122","journal-title":"Aktuelle Urologie"},{"key":"6358_CR20","doi-asserted-by":"crossref","unstructured":"Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, Agarwal N (2023) Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 43, e390166","DOI":"10.1200\/EDBK_390166"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06358-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:44:49Z","timestamp":1781642689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06358-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6358"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06358-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8137517\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study was in accordance with the Declaration of Helskini. Local Review of the ethics board was approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"257"}}